Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep1030 | Thyroid | ECE2023

Primary Thyroid Lymphoma: Clinical Course vs High Suvmax in Fdg-Pet

Lopes-Pinto Mariana , Aparicio David , Paula Ricca Lacerda Nobre M Caetano Ema , Dolores Lopez-Presa Maria , Joao Bugalho Maria

Introduction: Primary thyroid lymphomas (PTL) account for 5% of all thyroid malignancies. Treatment and prognosis depend on tumor subtype. Contrasting with diffuse large B-cell lymphomas (DLBCL), that have an aggressive clinical course and higher maximum standardized uptake value (SUVmax) in Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET), thyroid extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) usually show an indolen...

ea0041ep334 | Clinical case reports - Thyroid/Others | ECE2016

Erdheim-Chester disease and papillary thyroid carcinoma: case report of a common association in a rare disease

Aparicio David , Martins Nuno , Leichsenring Carlos , Rodrigues Alice , Joao Ana , Soares Antonio , Fragoso Marta , Marinho Rui , Rocha Ricardo , Sousa Marta , Gouminski Serguei , Sobrinho Cisaltina , Dias Wima , Afonso Enio , Geraldes Vasco , Nunes Vitor

Introdution: Erdheim-Chester disease is a rare multisystemic form of Non-langerhans cell histiocytosis CD67 positive, with approximately 550 published cases. Papillary carcinoma is the most common thyroid cancer with BRAF V600E the most common mutation. Both diseases may be associated to BRAF V600E mutation. If Erdheim- Chester disease is positive to this mutation on histiocytes, a specific pharmacolgical treatment is available, (vemurafenib), with better results.<p class=...